.png){kind=icon}
返回
Y
Yue Cao
university of kentucky
29H指数
118论文数
9.1K被引数
收录论文 36
发表时间
.png){kind=icon}
First-line (1L) zolbetuximab plus chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT plus GLOW一线（1L）zolbetuximab 联合化疗在 CLDN18.2 阳性、HER2 阴性、局部晚期（LA）不可切除或转移性胃或胃食管结合部（mG/GEJ）腺癌患者中的应用：SPOTLIGHT 和 GLOW 研究的合并最终分析.png)
ANNALS OF ONCOLOGY.png)
ANNALS OF ONCOLOGYIF65.4
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinomaANNALS OF ONCOLOGY
ANNALS OF ONCOLOGYIF65.4
PREAI
分享收藏Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinomaANNALS OF ONCOLOGY
ANNALS OF ONCOLOGYIF65.4
PREAI
分享收藏